drugset / Trial / NCT07371871
A Prospective, Single-arm, Exploratory Study of Trifluridine/Tipiracil (TAS-102) Combined With Apatinib as Third-line Therapy for Advanced Gastric Cancer
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of trifluridine/tipiracil (TAS-102) combined with apatinib as third-line therapy for advanced gastric cancer
Timeline
- Start
- 2026-01-08
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rivoceranib | Small molecule | 500 mg | — |
| Subject | Tipiracil | Small molecule | — | Oral |
| Subject | Trifluridine | Small molecule | — | Oral |